Related references
Note: Only part of the references are listed.Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature
Vinay Mathew Thomas et al.
HAEMOPHILIA (2022)
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
Koichiro Yoneyama et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Emicizumab for the treatment of acquired hemophilia A
Paul Knoebl et al.
BLOOD (2021)
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Michael U. Callaghan et al.
BLOOD (2021)
A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors
Koichiro Yoneyama et al.
BLOOD (2021)
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
Fredrik Jonsson et al.
CLINICAL PHARMACOKINETICS (2021)
Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A
Masahiro Takeyama et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Low immunogenicity of emicizumab in persons with haemophilia A
Christophe Schmitt et al.
HAEMOPHILIA (2021)
An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A
Masahiro Takeyama et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
International recommendations on the diagnosis and treatment of acquired hemophilia A
Andreas Tiede et al.
HAEMATOLOGICA (2020)
Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Sylvie Retout et al.
CLINICAL PHARMACOKINETICS (2020)
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
Joanne Adamkewicz et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Midori Shima et al.
HAEMOPHILIA (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre
Anita Arokszallasi et al.
BLOOD COAGULATION & FIBRINOLYSIS (2018)
Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies
K. Nogami et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A successful physiotherapy management case of a patient with acquired haemophilia A prior to factor VIII inhibitor eradication
M. Goto et al.
HAEMOPHILIA (2016)
Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study
Ezio Zanon et al.
THROMBOSIS RESEARCH (2015)
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
Andreas Tiede et al.
BLOOD (2015)
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A
Atsushi Muto et al.
BLOOD (2014)
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
A. Muto et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Zenjiro Sampei et al.
PLOS ONE (2013)
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
P. Knoebl et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation
Peter W. Collins et al.
BLOOD (2007)
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation
Charles R. M. Hay et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Share Paper
